Intravenous prostacyclin mitigates inhaled nitric oxide rebound effect: A case control study

Area of Science:

• Pediatric Cardiology
• Critical Care Medicine
• Pharmacology

Background:

• Extracorporeal membrane oxygenation (ECMO) can impair endothelial function, increasing pulmonary vascular resistance.
• Inhaled nitric oxide (iNO) is used for pulmonary hypertension post-cardiac surgery, but withdrawal can cause oxygenation issues.
• A rebound effect, defined as a 5% oxygen saturation decrease within 4 hours of iNO withdrawal, is a significant complication.

Purpose of the Study:

• To evaluate if intravenous prostacyclin administration can mitigate the oxygenation rebound effect after iNO withdrawal in pediatric patients.
• To assess the efficacy of prostacyclin in preventing post-iNO withdrawal complications in children with pulmonary hypertension.

Main Methods:

• A retrospective case-control study was conducted.
• Twelve children receiving iNO for pulmonary hypertension were given intravenous prostacyclin 24 hours before and during iNO withdrawal (Group 1).
• Twelve matched controls received iNO without pre-treatment prostacyclin (Group 2).

Main Results:

• The rebound effect occurred in only 1 of 12 children in the prostacyclin group (Group 1).
• In contrast, 8 of 12 children in the control group (Group 2) experienced the rebound effect (p = 0.0039).
• This indicates a significant protective effect of prostacyclin.

Conclusions:

• Intravenous prostacyclin administered prior to and during iNO withdrawal appears effective in mitigating the rebound oxygenation effect.
• Prostacyclin may be a valuable therapeutic option for managing pulmonary hypertension in pediatric patients undergoing iNO therapy.
• Further prospective studies are warranted to confirm these findings.